Key Highlights
- CVS delivered adjusted EPS of $2.57, surpassing analyst expectations of $2.18, representing the company’s fifth consecutive quarterly beat
- Total revenue reached $100.4 billion, significantly exceeding Wall Street’s $95 billion projection
- The medical benefit ratio showed improvement at 84.6%, compared to 87.3% in the prior-year period
- The company increased its full-year 2026 adjusted EPS forecast to $7.30–$7.50, elevated from the previous $7.00–$7.20 range
- Shares of CVS advanced 4.9% during premarket trading hours following the earnings announcement
CVS Health shares surged 4.9% in premarket activity Wednesday following the release of robust first-quarter results and an upward revision to its full-year forecast.
The healthcare giant reported adjusted earnings of $2.57 per share, exceeding the $2.18 consensus estimate from analysts. Total revenue reached $100.4 billion, surpassing the $95 billion figure Wall Street had anticipated.
The results represent the fifth consecutive quarter in which CVS has exceeded analyst expectations. The company has maintained a conservative stance on guidance while executing a comprehensive turnaround strategy following challenges throughout 2024.
Management elevated its full-year 2026 adjusted EPS guidance to a range of $7.30 to $7.50, revised upward from the prior range of $7.00 to $7.20. The company simultaneously increased its cash flow from operations projection to a minimum of $9.5 billion, raised from the previous $9 billion target.
Prior to Wednesday’s session, the stock had recorded a modest 1.7% year-to-date gain, underperforming the S&P 500’s 6% advance.
Aetna Shows Stronger Medical Cost Management
The most impressive metric came from the medical benefit ratio at the Aetna insurance division. The ratio registered at 84.6%, substantially below the 87.58% analyst forecast and representing a decline from 87.3% recorded in the same period last year.
This ratio indicates the percentage of premium revenue allocated to medical care expenses. A lower figure demonstrates greater profitability for the insurer. CFO Brian Newman attributed the enhanced performance to improved forecasting capabilities and stronger cost management practices.
UnitedHealth and Humana similarly exceeded analyst projections on this measure during Q1, indicating widespread enhancement among Medicare Advantage providers.
The federal government announced in April that 2027 reimbursement rates to Medicare Advantage insurers would increase by an average of 2.48%. Newman indicated this increase remains below anticipated cost growth for the coming year, potentially requiring CVS to modify pricing structures or benefit offerings.
Health Services Gains While Retail Pharmacy Faces Headwinds
The health services division, which includes the Caremark pharmacy benefit manager, recorded revenue growth of 11% to reach $48.2 billion. Operating income totaled $1.34 billion, meeting analyst projections.
Newman credited a more favorable drug mix for supporting Caremark’s performance. Leerink analyst Michael Cherny had previously identified reaching $1.3 billion in adjusted operating income for this segment as a critical milestone for rebuilding investor trust.
Pharmacy benefit managers continue to encounter scrutiny from legislators and regulatory bodies regarding drug pricing methodologies. CVS currently has a pending FTC settlement concerning allegations that its PBM contributed to elevated insulin costs, claims the company disputes.
The company is challenging a Tennessee legislative proposal that would prohibit PBMs from operating pharmacies within state boundaries. The measure has cleared the state legislature and awaits gubernatorial consideration.
The retail pharmacy division generated a 5% revenue increase in 2025 following its acquisition of pharmacy locations from Rite Aid, bringing in 9 million additional customers. However, operating income for this unit declined 8.8% year-over-year during Q1.
CVS pointed to regulatory modifications affecting specific drug pricing, reduced cold and flu season activity, and weather-related disruptions — including temporary store closures from snowstorms — as contributing factors to the pharmacy business challenges.
